<< Back to News

FDA Grants Accelerated Approval for POLIVY™

On June 10, 2019, the US Food and Drug Administration (FDA) granted accelerated approval for POLIVY™ (polatuzumab vedotin-piiq) in combination with bendamustine and rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least 2 prior therapies.

POLIVY Access Solutions is your resource for access and reimbursement support after POLIVY is prescribed. We can helpyour patients and practice by providing:

  • Benefits investigations (BIs)
  • Prior authorization (PA) resources
  • Information about authorized specialty distributors
  • Sample billing and coding information
  • Resources for appeals
  • Referrals to co-pay support
  • Patient assistance options

A list of authorized specialty distributors is available at Genentech-Access.com/POLIVY.

For more information about POLIVY patient access, please call your POLIVY Access Solutions Case Manager at (888) 249-4918.

POLIVY Sample Coding and Distribution Brochure

POLIVY Master USPI